FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## CIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES IN BENEFIC
obligations may continue. See Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Excha

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Dineen John M.</u>						2. Issuer Name <b>and</b> Ticker or Trading Symbol  MERRIMACK PHARMACEUTICALS  INC [ MACK ]									ck all appli Directo	cable) or	g Per	son(s) to Iss	vner	
	RRIMACK	irst) ( PHARMACEU QUARE, SUITE		INC.		3. Date of Earliest Transaction (Month/Day/Year) 09/13/2017									officer below)	(give title		Other (s below)	specify	
(Street) CAMBR (City)	IDGE M	IA (	02139 (Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	ndividual or Joint/Group Filing (Check Applicable c)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transac Date (Month/Da					action	2A. Deemed Execution Date,			3. Transa Code (I	4. Secur		ities Acquired (A) of (D) (Instr. 3, 4		or	5. Amou Securitie Benefici Owned F Reporter Transact	int of es Formally (D) (I) (I) (I) (I) (I) (I) (I) (I) (I) (I		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		n of		6. Date Exe Expiration (Month/Da	Date		Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		rity	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)	
					Code	v	(A)		Date Exercisabl		xpiration ate	Title	Amo or Num of Shar	ber						
Stock Option (right to buy)	\$13.99	09/13/2017			A		7,500		(1)	09	9/12/2027	Common Stock	7,5	00	\$0.00	7,500		D		

**Explanation of Responses:** 

1. This option is fully vested.

## Remarks:

/s/ Brian J. Kickham, attorney-09/15/2017 in-fact

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.